Cargando…
Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia
The aim of this cohort study was to compare a condensed schedule of consolidation therapy with high-dose cytarabine on days 1, 2 and 3 (HDAC-123) with the HDAC schedule given on days 1, 3 and 5 (HDAC-135) as well as to evaluate the prophylactic use of pegfilgrastim after chemotherapy in younger pati...
Autores principales: | Jaramillo, S, Benner, A, Krauter, J, Martin, H, Kindler, T, Bentz, M, Salih, H R, Held, G, Köhne, C-H, Götze, K, Lübbert, M, Kündgen, A, Brossart, P, Wattad, M, Salwender, H, Hertenstein, B, Nachbaur, D, Wulf, G, Horst, H-A, Kirchen, H, Fiedler, W, Raghavachar, A, Russ, G, Kremers, S, Koller, E, Runde, V, Heil, G, Weber, D, Göhring, G, Döhner, K, Ganser, A, Döhner, H, Schlenk, R F |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5518888/ https://www.ncbi.nlm.nih.gov/pubmed/28548643 http://dx.doi.org/10.1038/bcj.2017.45 |
Ejemplares similares
-
All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 study
por: Schlenk, Richard F., et al.
Publicado: (2016) -
Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia
por: Schlenk, R F, et al.
Publicado: (2017) -
Randomized phase-III study of low-dose cytarabine and etoposide + /− all-trans retinoic acid in older unfit patients with NPM1-mutated acute myeloid leukemia
por: Schlenk, R. F., et al.
Publicado: (2023) -
Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO)
por: Nagel, Gabriele, et al.
Publicado: (2017) -
Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study
por: Schlenk, Richard F., et al.
Publicado: (2020)